Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||PLX4720 + Tivozanib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|PLX4720||PLX-4720|PLX 4720||BRAF Inhibitor 21||PLX4720 is a 7-azaindole derivative and RAF kinase inhibitor with greater affinity for BRAF V600E than BRAF wild-type, which may induce cell cycle arrest and apoptosis, and lead to tumor growth inhibition and regression (PMID: 18287029).|
|Tivozanib||Fotivda||AV-951|AV951|KIL-8951|KRN 951|KRN-951||VEGFR Inhibitor (Pan) 33||Fotivda (tivozanib) inhibits VEGFR1-3, which may result in decreased tumor angiogenesis and proliferation and increased cell death (PMID: 23788831, PMID: 31810797, PMID: 32547647). Fotivda(tivozanib) is FDA approved for use in adult patients with relapsed or refractory advanced renal cell carcinoma who have received two or more prior systemic therapies (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF V600E||melanoma||sensitive||PLX4720 + Tivozanib||Preclinical||Actionable||In a preclinical study, PLX4720 and Tivozanib (AV-951) worked synergistically to inhibit cell growth in PLX4720-resistant melanoma cell lines harboring BRAF V600E in culture (PMID: 26461489).||26461489|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|